Significant Associations of IgG Glycan Structures With Chronic Graft-Versus-Host Disease Manifestations: Results of the Cross-Sectional NIH Cohort Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Aug 2

PMID 34335560

Citations 1

Authors

Ema Prenc

Drazen Pulanic

Maja Pucic-Bakovic

Ivo Ugrina

Lana Desnica

Milan Milosevic

Filip Pirsl

Sandra Mitchell

Jeremy Rose

Radovan Vrhovac

Damir Nemet

Gordan Lauc

Steven Z Pavletic

Affiliations

Soon will be listed here.

Abstract

Chronic graft-versus-host disease (cGvHD) is a systemic alloimmune and autoimmune disorder and a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). The disease is characterized by an altered homeostasis of the humoral immune response. Immunoglobulin G (IgG) glycoprotein is the main effector molecule of the humoral immune response. Changes in IgG glycosylation are associated with a number of autoimmune diseases. IgG glycosylation analysis was done by the means of liquid chromatography in the National Institutes of Health (NIH) cohort of 213 cGvHD patients. The results showed statistically significant differences with regards to cGvHD NIH joint/fascia and skin score, disease activity and intensity of systemic immunosuppression. ROC analysis confirmed that IgG glycosylation increases specificity and sensitivity of models using laboratory parameters and markers of inflammation associated with cGvHD (eosinophil count, complement components C3 and C4 and inflammation markers: albumin, CRP and thrombocyte count). This research shows that IgG glycosylation may play a significant role in cGvHD pathology. Further research could contribute to the understanding of the disease biology and lead to the clinical biomarker development to allow personalized approaches to chronic GvHD therapy.

Citing Articles

The impact of immunoglobulin G N-glycosylation level on COVID-19 outcome: evidence from a Mendelian randomization study.

Long F, Xiao C, Cui H, Wang W, Jiang Z, Tang M Front Immunol. 2023; 14:1217444.

PMID: 37662938 PMC: 10472139. DOI: 10.3389/fimmu.2023.1217444.

References

de Jong S, Selman M, Adegnika A, Amoah A, van Riet E, Kruize Y . IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Sci Rep. 2016; 6:28207. PMC: 4910062. DOI: 10.1038/srep28207. View

Lauc G, Huffman J, Pucic M, Zgaga L, Adamczyk B, Muzinic A . Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013; 9(1):e1003225. PMC: 3561084. DOI: 10.1371/journal.pgen.1003225. View

de Haan N, Van Tol M, Driessen G, Wuhrer M, Lankester A . Immunoglobulin G Fragment Crystallizable Glycosylation After Hematopoietic Stem Cell Transplantation Is Dissimilar to Donor Profiles. Front Immunol. 2018; 9:1238. PMC: 5994695. DOI: 10.3389/fimmu.2018.01238. View

Vidarsson G, Dekkers G, Rispens T . IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014; 5:520. PMC: 4202688. DOI: 10.3389/fimmu.2014.00520. View

Davies J, Jiang L, Pan L, LaBarre M, Anderson D, Reff M . Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng. 2001; 74(4):288-94. View

Paczesny S, Hakim F, Pidala J, Cooke K, Lathrop J, Griffith L . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015; 21(5):780-92. PMC: 4408233. DOI: 10.1016/j.bbmt.2015.01.003. View

Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, Ishii S . IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol. 2008; 103(5):1173-81. DOI: 10.1111/j.1572-0241.2007.01699.x. View

Parekh R, Roitt I, Isenberg D, Dwek R, ANSELL B, Rademacher T . Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet. 1988; 1(8592):966-9. DOI: 10.1016/s0140-6736(88)91781-3. View

Ercan A, Cui J, Chatterton D, Deane K, Hazen M, Brintnell W . Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010; 62(8):2239-48. PMC: 4118465. DOI: 10.1002/art.27533. View

10.

Gudelj I, Salo P, Trbojevic-Akmacic I, Albers M, Primorac D, Perola M . Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(6 Pt A):2034-2039. DOI: 10.1016/j.bbadis.2018.03.018. View

11.

Plomp R, Ruhaak L, Uh H, Reiding K, Selman M, Houwing-Duistermaat J . Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep. 2017; 7(1):12325. PMC: 5615071. DOI: 10.1038/s41598-017-12495-0. View

12.

Filipovich A . Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008; 21(2):251-7. DOI: 10.1016/j.beha.2008.02.008. View

13.

Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch J . General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A. 2013; 110(24):9868-72. PMC: 3683708. DOI: 10.1073/pnas.1307864110. View

14.

Schultz K, Miklos D, Fowler D, Cooke K, Shizuru J, Zorn E . Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006; 12(2):126-37. DOI: 10.1016/j.bbmt.2005.11.010. View

15.

Jefferis R . Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009; 8(3):226-34. DOI: 10.1038/nrd2804. View

16.

Bakovic M, Selman M, Hoffmann M, Rudan I, Campbell H, Deelder A . High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res. 2013; 12(2):821-31. DOI: 10.1021/pr300887z. View

17.

Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I . Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011; 108(31):12669-74. PMC: 3150898. DOI: 10.1073/pnas.1108455108. View

18.

Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O . High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011; 10(10):M111.010090. PMC: 3205872. DOI: 10.1074/mcp.M111.010090. View

19.

Malhotra R, Wormald M, Rudd P, Fischer P, Dwek R, Sim R . Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995; 1(3):237-43. DOI: 10.1038/nm0395-237. View

20.

Gornik O, Lauc G . Glycosylation of serum proteins in inflammatory diseases. Dis Markers. 2009; 25(4-5):267-78. PMC: 3827815. DOI: 10.1155/2008/493289. View